Therapeutic Uses
Anti-Thrombotics
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
Ticagrelor-d7, 1265911-55-4
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 95 %
Hazard Compound
No -Refer MSDS for accurate information
Ticagrelor-d7 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Ticagrelor-d7 usage and description
Ticagrelor is an antiplatelet medication used to prevent blood clots in patients with acute coronary syndrome (ACS) and other conditions that increase the risk of heart attacks. Ticagrelor D7 is a deuterated form of Ticagrelor, which means that some hydrogen atoms in the molecular structure of the drug are replaced with deuterium atoms. This modification makes the drug more stable and increases its bioavailability, which can lead to more effective and consistent therapeutic outcomes.
Ticagrelor D7 works by blocking the P2Y12 receptor on platelets, which prevents them from aggregating and forming blood clots. This mechanism of action makes Ticagrelor D7 an important medication for patients who have undergone stent placement or who are at high risk for cardiovascular events.
The chemical formula of Ticagrelor D7 is C23H14D7F2N6O4S, and its molecular weight is 530.62 g/mol. The drug is administered orally as a tablet, and its recommended dosage is 90 mg twice daily for up to 12 months, depending on the patient's condition and response to treatment.
Like all medications, Ticagrelor D7 may cause side effects, including bleeding, shortness of breath, headache, and nausea. Patients taking Ticagrelor D7 should be closely monitored for signs of bleeding and other adverse reactions.
In conclusion, Ticagrelor D7 is a potent antiplatelet medication used to prevent blood clots in patients with ACS and other cardiovascular conditions. Its deuterated form enhances its stability and bioavailability, making it an effective and reliable treatment option for these patients.
